Pamoic acid， disodium salt , ≥98.0%(HPLC) , 6640-22-8

Synonym(s):
4,4′-Methylenebis(3-hydroxy-2-naphthoic acid);Embonic acid;Sodium pamoate

CAS NO.：6640-22-8

Empirical Formula: C23H14Na2O6

Molecular Weight: 432.33

MDL number: MFCD00036183

EINECS: 229-653-1

PRODUCT Properties

• Melting point: 300 °C
• Density: 1.55[at 20℃]
• vapor pressure: 0.001Pa at 25℃
• storage temp.: Desiccate at RT
• solubility: insoluble in EtOH; ≥18 mg/mL in H2O; ≥28.6 mg/mL in DMSO
• form: solid
• color: Pale yellow
• Water Solubility: 43g/L at 20℃
• InChI: 1S/C23H16O6.Na.H/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;;/h1-10,24-25H,11H2,(H,26,27)(H,28,29)
• InChIKey: ZRZSXMUASGHHKP-UHFFFAOYSA-N
• SMILES: [Na].OC(=O)c1cc2ccccc2c(Cc3c(O)c(cc4ccccc34)C(O)=O)c1O
• LogP: -3.2 at 20℃
• CAS DataBase Reference: 6640-22-8(CAS DataBase Reference)
• EPA Substance Registry System: 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt (6640-22-8)

Description and Uses

Pamoic acid disodium salt, a supposedly inactive component in many formulations of drugs used to modulate release, is a potent agonist of the orphan receptor GPR35. GPR35 is a class A, rhodopsin-like G protein-coupled receptor (GPCR), strongly expressed in the lower intestine and colon, dorsal root ganglia, as well as a variety of immune cells including monocytes and dendritic cells. Targeting GPR35 provides potential therapeutic opportunities in a range of conditions, such as inflammation, pain and cancer.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• PPE: Eyeshields, Gloves, type N95 (US)
• Hazard Codes: Xn
• Risk Statements: 20/21/22-37/38-41-48
• Safety Statements: 24/25-45-36/37/39-26-22
• WGK Germany: 3
• TSCA: TSCA listed
• HS Code: 2918.29.7500
• Storage Class: 11 - Combustible Solids